Even after a string of acquisitions, Dow AgroSciences is a bit player in the seed business. But the new genetically
modified corn it developed with St. Louis-based giant Monsanto Co. finally provides the breakthrough product that could grow
its seed sales substantially.
Two chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—low-cost and all over the world.
Favorable article in prestigious journal could draw attention to Carmel biotech startup.
Eli Lilly and Co.’s top rising-star drug has been approved by U.S. regulators for a new use, an event that could boost sales of
the medication. Alimta, a lung cancer drug, was approved as a maintenance therapy for non-small cell lung cancer
for certain patients, Lilly announced today.
The Indiana Minority Supplier Development Council has made life sciences companies its latest target—part of an even larger effort to attract minorities to the burgeoning life sciences industry under
way on a national scale.
West Lafayette-based life sciences contract research firm Bioanalytical Systems Inc. has five directors on its board. If company
founder Pete Kissinger has his way, four of them will soon be replaced.
Two chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—a model that’s low-cost
and can spread around the world.
Ma quande lingues coalesce, t va semblar un simplificat Angles, quam un skeptic Cambridge amico dit me que Occidental es.
Compared with some of his pharmaceutical CEO peers these days, John Lechleiter has his company on a diet. Instead of using a mega-merger to bulk up before the famine that patent expirations will bring on the industry next year,
Lechleiter has Eli Lilly and Co. burning management fat while looking for smaller companies to munch on.
It took Pete and Candace Kissinger 33 years to build West Lafayette-based Bioanalytical Systems Inc. into one of the largest
contract research firms in Indiana’s life science sector. It took just a year and a half for them to turn against the company’s new management.
Scientists are using a new stem-cell technique that may someday revolutionize care for disorders as diverse as diabetes, Alzheimer’s
disease and muscular dystrophy.
Indiana and Purdue universities are well-positioned to take advantage of the $11.5 billion available for life sciences and
biotech research from the federal stimulus package.
Indiana is becoming not only a hotbed of “pharmacogenomics” research, but also a trailblazer in finding practical ways to
use it on the practitioner level.
The Indiana Innovation Alliance will bring together researchers from both IU and Purdue and keep much intellectual property innovation in Indiana.
Eli Lilly & Co. executives are making many trips to Washington to argue for 14 years of sales exclusivity for new drugs made
from cells.
Three entrepreneurs from the medical and software realms are herding angels to invest in upstart life sciences companies in
Indiana.
Lawyers holding doctorates in biotech, biology, chemistry and computer sciences are in high demand by firms with strong intellectual
property practices.
Financially strapped Dow Chemical Co. acknowledges it may sell Indianapolis-based Dow AgroSciences LLC, the ag-chemicals-and-biotech
firm that’s one of the biggest jewels in the city’s life sciences crown.
The Central Indiana Corporate Partnership—the parent of the BioCrossroads, TechPoint and Conexus industry cluster initiatives—let it be known last month that there would be a fourth leg to its economic development stool: clean technology.
NASA begins to award more grants to Indiana firms and universities.
